Maxion Therapeutics’ Breakthrough Science and Innovation Recognised in PwC UK’s Life Sciences Future50 list
- Maxion selected from over 500 UK-based companies, based on its world-class science and innovation
- Specific recognition for company’s work on unlocking intractable drug targets, with its KnotBody® platform overcoming challenges in ion channel and GPCR antibody development
Cambridge, UK – Maxion Therapeutics has been featured in PwC UK’s new Life Sciences Future50 list, which aims to shine a spotlight on the transformational science and innovation pioneered by UK life science companies. The list, compiled in a recently-published report, recognises Maxion’s breakthrough science and points of differentiation, as well as the excellent track record and scientific achievement of our co-founders, CEO Dr John McCafferty and CSO Dr Aneesh Karatt Vellatt. To create the list, PwC UK screened data for relevant UK-based businesses that raised private financing of USD $10 million in aggregate and had a funding event since 2018. An assessment framework was then applied to attain a shortlist of 190 companies, focused on impact potential, breakthrough science and innovation, differentiation, and maturity. The final list of 50 companies was then selected from the shortlist based upon scoring and cross-review to ensure representation from multiple sub-sectors and therapeutic areas.
John McCafferty, Co-founder and CEO, Maxion Therapeutics, commented:
Aneesh Karatt Vellatt, Co-founder and CSO, Maxion Therapeutics, said:
At Maxion we are applying our patented KnotBody technology to generate potent, selective, and long-acting antibody-like drugs. KnotBody technology combines the benefits of naturally occurring mini-proteins, which have ion channel modulating activity, with antibodies, using state-of-the-art phage and mammalian display technologies. The resulting fusion protein, which combines the drug-like benefits of both molecules, helps address key challenges in ion channel and GPCR drug discovery. Our lead KnotBody programme is progressing rapidly towards preclinical development with first-in-class and best-in-class potential.
Contact
About Maxion Therapeutics
Maxion Therapeutics is a biotechnology company developing antibody-based drugs for previously untreatable ion channel- and G protein-coupled receptor (GPCR)-driven diseases, including autoimmune conditions, chronic pain, and cardiovascular disease.
The Company is developing a pipeline of potentially first- and best-in-class therapeutics using its proprietary KnotBody® technology to generate potent, selective, and long-acting therapeutics by combining naturally occurring mini-proteins (‘knottins’) with antibodies using state-of-the-art phage and mammalian display technologies. Maxion was founded in 2020 by highly respected biotech entrepreneurs and scientists Dr John McCafferty, CTO and Dr Aneesh Karatt-Vellatt, CSO. Dr McCafferty previously co-invented antibody phage display, which was the subject of the 2018 Nobel Prize in Chemistry awarded to his co-inventor Sir Gregory Winter. Maxion’s portfolio and growth is being advanced by a team of highly experienced leaders in the discovery and development of antibody-based drugs. The Company is based near Cambridge, UK and is backed by international blue-chip investors.
For more information, please visit: https://www.maxiontherapeutics.com/
